Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Blood Testing Distinguishes Benign Tumors from Precancerous Condition

By LabMedica International staff writers
Posted on 15 Sep 2021
The leading cause of mortality for patients with the neurofibromatosis type 1 (NF1) cancer predisposition syndrome is the development of malignant peripheral nerve sheath tumor (MPNST), an aggressive soft tissue sarcoma. More...
In the setting of NF1, this cancer type frequently arises from within its common and benign precursor, plexiform neurofibroma (PN).

Despite the high incidence and mortality of MPNST in the NF1 population, screening for malignant transformation and monitoring of MPNST is challenging. Clinical examination has poor sensitivity and may only signify MPNST when a PN lesion is showing sudden growth or causing severe pain. Serial PN biopsies are impractical as 9% to 21% of NF1 patients will have multiple PN, with varying levels of malignant potential requiring surveillance.

Specialized Oncologists at Washington University School of Medicine (St. Louis, MO, USA) and their colleagues assessed cell-free DNA (cfDNA) in blood plasma samples from 16 unaffected volunteer individuals and 37 individuals with NF1 — including samples from 23 PN patients and 46 samples from 14 individuals with MPNST.

The team extracted cell-free DNA (cfDNA) was from plasma using the QIAamp Circulating Nucleic Acid kit (Qiagen, Hilden, Germany). Extracted DNA concentration was measured using the Qubit dsDNA High-Sensitivity assay (Thermo Fisher Scientific, Waltham, MA, USA), and cfDNA concentration and quality were assessed using a Bioanalyzer or Tapestation (Agilent Technologies, Santa Clara, CA, USA). Constructed libraries were balanced, pooled, and sequenced using 150 bp paired-end reads on a NovaSeq or HiSeq 4000 (Illumina, San Diego, CA, USA).

The investigators reported that based on cfDNA fragment sizes, copy number profiles, and genomic instability patterns, they developed a classifier that could discriminate between individuals with or without the tumor conditions while distinguishing the malignant and benign forms of disease with 86% accuracy (75% sensitivity and 91% specificity) in untreated individuals. In samples collected over time, the team reported, the cfDNA-based tool correctly classified 89% of the MPNST and PN cases, with 83% sensitivity and a specificity of around 91%. When the investigators quantified ctDNA in serial MPNST samples for their proof-of-concept analyses, they found that the approach may help in tracking treatment response and detecting relapse-related minimal residual disease after treatment at time points where MRD did not show up by radiographic imaging.

The scientists noted that plasma cfDNA from MPNST and PN patients harbored focal copy number loss of NF1 not found in healthy donors and that MPNST patient cfDNA also had significantly greater tumor genomic instability compared to PN, with copy number alterations in key genomic loci previously observed in MPNST tissue, which enabled sensitive and specific liquid biopsy discrimination of MPNST from PN.

The authors concluded that tumor fraction levels derived from cfDNA fragment size and copy number alteration analysis of plasma cfDNA using ultra-low-pass whole genome sequencing (ULP-WGS) significantly correlated with MPNST tumor burden, accurately distinguished MPNST from its benign PN precursor, and dynamically correlated with treatment response. In the future, their findings could form the basis for improved early cancer detection and monitoring in high-risk cancer-predisposed populations. The study was published on August 31, 2021 in the journal PLOS Medicine.

Related Links:
Washington University School of Medicine
Qiagen
Thermo Fisher Scientific
Agilent Technologies
Illumina



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: iStock

AMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health

Advances in molecular diagnostics are creating new opportunities to improve the detection of sexually transmitted infections, identify antibiotic resistance, and assess cancer recurrence risk in women.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.